Overview

Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of temozolomide in treating young patients with refractory or recurrent leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Children's Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Dacarbazine
Temozolomide